Tang Na, Zhang Yaoyao, Sadigh Yashar, Moffat Katy, Shen Zhiqiang, Nair Venugopal, Yao Yongxiu
Viral Oncogenesis Group & UK-China Centre of Excellence for Research on Avian Diseases, The Pirbright Institute, Pirbright, Surrey GU24 ONF, UK.
Postdoctoral workstation & UK-China Centre of Excellence for Research on Avian Diseases, Shandong Binzhou Animal Science and Veterinary Medicine Academy, Binzhou 256600, China.
Vaccines (Basel). 2020 Feb 21;8(1):97. doi: 10.3390/vaccines8010097.
Herpesvirus of turkeys (HVT), used originally as a vaccine against Marek's disease (MD), has recently been shown to be a highly effective viral vector for generation of recombinant vaccines that deliver protective antigens of other avian pathogens. Until the recent launch of commercial HVT-vectored dual insert vaccines, most of the HVT-vectored vaccines in the market carry a single foreign gene and are usually developed with slow and less efficient conventional recombination methods. There is immense value in developing multivalent HVT-vectored vaccines capable of inducing simultaneous protection against multiple avian pathogens, particularly to overcome the interference between individual recombinant HVT vaccines. Here we demonstrate the use of a previously developed CRISPR/Cas9 gene editing protocol for the insertion of ILTV gD-gI and the H9N2 AIV hemagglutinin expression cassettes into the distinct locations of the recombinant HVT-IBDV VP2 viral genome, to generate the triple insert HVT-VP2-gDgI-HA recombinant vaccine. The insertion, protein expression, and stability of each insert were then evaluated by PCR, immunostaining and Western blot analyses. The successful generation of the first triple insert recombinant HVT vaccine with the potential for the simultaneous protection against three major avian viral diseases in addition to MD is a major innovation in vaccination-based control of major poultry diseases.
火鸡疱疹病毒(HVT)最初用作抗马立克氏病(MD)的疫苗,最近已被证明是一种高效的病毒载体,可用于生产能递送其他禽病原体保护性抗原的重组疫苗。在近期商业化的HVT载体双插入疫苗推出之前,市场上的大多数HVT载体疫苗都携带单个外源基因,并且通常采用缓慢且效率较低的传统重组方法开发。开发能够同时诱导针对多种禽病原体的保护作用的多价HVT载体疫苗具有巨大价值,特别是为了克服单个重组HVT疫苗之间的干扰。在此,我们展示了使用先前开发的CRISPR/Cas9基因编辑方案,将传染性喉气管炎病毒(ILTV)gD-gI和H9N2禽流感病毒(AIV)血凝素表达盒插入重组HVT-传染性法氏囊病病毒(IBDV)VP2病毒基因组的不同位置,以生成三插入HVT-VP2-gDgI-HA重组疫苗。然后通过聚合酶链式反应(PCR)、免疫染色和蛋白质免疫印迹分析评估每个插入片段的插入情况、蛋白质表达和稳定性。成功生成首个三插入重组HVT疫苗,除了能预防MD外,还具有同时预防三种主要禽病毒性疾病的潜力,这是基于疫苗接种控制主要家禽疾病方面的一项重大创新。